SCHEMBL342723

SCHEMBL342723

Cn1cc(C(=O)c2cc(Cl)ccc2N)nn1

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.50
ESRRA P11474 12/20 0.47
NOS2 P35228 1/20 0.43
FADS1 O60427 1/20 0.43
KCNMA1 Q12791 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15308435 0.86 ESRRA (0.44) ESRRAKCNMA1
SCHEMBL343320 0.83 ESRRA (0.49) ESRRA
SCHEMBL343131 0.80 RECQL (0.50) RECQLNOS2FADS1
SCHEMBL9540049 0.76 RECQL (0.79) RECQLNOS2FADS1
SCHEMBL343083 0.74 RECQL (0.50) RECQLNOS2FADS1
SCHEMBL11687575 0.73 IDO1 (0.46)
SCHEMBL343579 0.72 RECQL (0.51) RECQLNOS2FADS1
SCHEMBL344499 0.72 RECQL (0.51) RECQLNOS2FADS1
SCHEMBL27983522 0.72 ESRRA (0.76) ESRRAKCNMA1
SCHEMBL31366584 0.72 RECQL (0.58) RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-20170369483-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2017-12-28 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
US-20060111351-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2006-05-25 US disclosed
WO-2005112925-A1 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2005-12-01 WO disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20120014997-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20060111351-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20170369483-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20090163498-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885ESRRA 848/4885NOS2 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.